Lilly, Boehringer diabetes drug cuts heart attack, stroke risk in trial
August 20, 2015 at 09:51 AM EDT
Aug 20 (Reuters) - A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday.